Literature DB >> 22246490

Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia.

Kohei Hosokawa1, Hirohito Yamazaki, Masaru Nishitsuji, Satoshi Kobayashi, Akiyoshi Takami, Masaki Fujimura, Shinji Nakao.   

Abstract

We report a case of pulmonary veno-occlusive disease (PVOD) following allogeneic bone marrow transplantation (BMT) for the treatment of acute myeloid leukemia (AML) from an HLA mismatched mother using a reduced-intensity conditioning (RIC) regimen including gemtuzumab ozogamicin. The patient was a 21-year-old male who complained of dyspnea with hypoxemia followed by loss of consciousness. The abnormalities in chest CT and echocardiography were compatible with a diagnosis of PVOD. Treatment with 1 mg/kg of oral prednisolone resolved dyspnea and hypoxemia within a few days, and chest CT abnormalities disappeared in a week. This report is the first to describe PVOD following RIC stem cell transplantation.

Entities:  

Mesh:

Year:  2012        PMID: 22246490     DOI: 10.2169/internalmedicine.51.6302

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.

Authors:  M S Zinter; A Melton; A J Sabnis; C C Dvorak; B M Elicker; H M Nawaytou; R J Kameny; J R Fineman
Journal:  Leuk Lymphoma       Date:  2017-09-28

2.  Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series.

Authors:  Lee Gazourian; Laura Spring; Emily Meserve; David Hwang; Alejandro A Diaz; Samuel Y Ash; Vincent T Ho; Lynette M Sholl; George R Washko
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-28       Impact factor: 5.742

3.  Successful treatment of pulmonary hypertension with beraprost and sildenafil after cord blood transplantation for infantile leukemia.

Authors:  Nozomu Kawashima; Masanobu Ikoma; Yuko Sekiya; Atsushi Narita; Nao Yoshida; Kimikazu Matsumoto; Tameo Hatano; Koji Kato
Journal:  Int J Hematol       Date:  2012-12-15       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.